# John Craighead

> John Craighead is a cell biologist and biotechnology executive who became chief executive officer of Chicago-based Syntax Bio in 2025. Across more than two decades, he has moved between science, equity research, investor relations, corporate development, finance and operations at organizations including Lehman Brothers, Human Genome Sciences, Sanofi, Atara Biotherapeutics, GRAIL, Elpiscience and HALO Precision Diagnostics. At Syntax Bio, he is leading the commercial and organizational buildout around Cellgorithm, a CRISPR-based platform designed to make stem-cell differentiation faster, more reproducible and more scalable.

- **Role:** Chief Executive Officer at Syntax Bio
- **Organizations:** Syntax Bio, HALO Precision Diagnostics, Elpiscience Biopharmaceuticals, GRAIL, Atara Biotherapeutics, Sanofi, Human Genome Sciences, Lehman Brothers, Scripps Research, St. Olaf College
- **Education:** B.A. in Chemistry and Molecular Biology, St. Olaf College, Ph.D. in Cell Biology; National Science Foundation Graduate Research Fellow, The Scripps Research Institute
- **Known for:** Received a National Science Foundation Graduate Research Fellowship., Co-authored a widely cited 2014 Nature Biotechnology analysis of clinical development success rates for investigational drugs., Held senior strategy, corporate development and investor relations responsibilities at GRAIL during its proposed IPO and acquisition period.

## Career timeline

- **1996-2000** — Studied chemistry and molecular biology at St. Olaf College.
- **2000-2004** — Completed doctoral training in cell biology at The Scripps Research Institute as a National Science Foundation Graduate Research Fellow.
- **By 2008** — Worked as an equity research analyst at Lehman Brothers.
- **2008-2021** — Held leadership roles at Human Genome Sciences, Sanofi, Atara Biotherapeutics and GRAIL across investor relations, corporate communications, strategy and corporate development.
- **2014** — Co-authored the Nature Biotechnology paper 'Clinical development success rates for investigational drugs.'
- **2022** — Joined Elpiscience Biopharmaceuticals as chief financial officer, leading finance and corporate development.
- **2023** — Joined HALO Precision Diagnostics as chief operating officer and chief financial officer.
- **2025** — Became chief executive officer and a board director at Syntax Bio.
- **2026** — Led Syntax Bio through an expanded $14.4 million Series A and a series of research and development collaborations.

## Achievements

- Received a National Science Foundation Graduate Research Fellowship.
- Co-authored a widely cited 2014 Nature Biotechnology analysis of clinical development success rates for investigational drugs.
- Held senior strategy, corporate development and investor relations responsibilities at GRAIL during its proposed IPO and acquisition period.
- Led finance and corporate development at Elpiscience Biopharmaceuticals as chief financial officer.
- Was appointed chief executive officer of Syntax Bio in 2025.
- Led Syntax Bio during the 2026 expansion of its Series A to $14.4 million, bringing reported total funding to more than $25 million.

## Latest updates

- **2026-06** — Syntax Bio expanded its Series A to $14.4 million, taking reported total funding above $25 million, and added executive, board and scientific advisory leadership.
- **2026-06** — Syntax Bio announced research and development collaborations with Mayo Clinic, Ajinomoto Health & Nutrition North America and Applied StemCell.
- **2025-12** — Syntax Bio announced peer-reviewed Science Advances research describing programmable, sequential control of gene activity in human stem cells.
- **2025-11** — Craighead discussed single-cell RNA sequencing, bulk RNA sequencing and genomic integrity assays as quality tools for engineered-cell development and manufacturing.

## Links

- Website: https://www.syntax-bio.com/
- LinkedIn: https://www.linkedin.com/in/biotechanalyst

---

Profile page: https://yespress.io/john-craighead
Published by YesPress — https://yespress.io
Last updated: 2026-08-18